Should the patients with advanced hepatocellular carcinoma get benefits from immunocheckpoint inhibitors and tyrosine kinase inhibitor combination therapy?

Yu Shuangjie, Li Yuanyuan, Bi Jingfeng, et al

Journal of Practical Hepatology . 2023, (6): 891 -894 . DOI: 10.3969/j.issn.1672-5069.2023.06.031